U.S. Judge upholds Ability patent; GSK's fish oil med fails AF study;

@FiercePharma: Pfizer plots more post-merger job cuts. Article  | Follow @FiercePharma 

> A federal judge has upheld the validity of a U.S. patent for Abilify, a ruling for Otsuka Pharmaceutical and partner Bristol-Myers Squibb  that keeps generic versions of the antipsychotic drug out of the United States until April 2015. Report

> A study of more than 600 patients who took GlaxoSmithKline's prescription-strength fish oil drug, Lovaza, for six months showed it did not keep atrial fibrillation at bay, researchers found. Article

> A drug used to protect the kidneys from contrast dye during X-rays of the heart's blood vessels doesn't work, researchers said, citing a large study that may change the way patients are treated. Story

> One in 10 lower level jobs in the Irish pharmaceutical sector will disappear within the next five years, a new report says, but this loss of 2,500 jobs could be balanced by the creation of additional high-quality positions if the sector gets the right kind of graduates. Report

> Utah has filed suit against GlaxoSmithKine (GSK), saying it illegally marketed Avandia as a "wonder drug" to fight Type 2 diabetes. Item

> U.S. regulators approved the use of Shire's attention-deficit hyperactivity disorder drug Vyvanse in adolescents aged 13-17 years, adding to its prior indications for children aged six to 12 years and adults. Report

> Drug-resistant infections with the "superbug" Clostridium difficile are rising in Europe and are widespread, scientists said, but there are big variations in the way health authorities monitor them. News

Biotech News

 @FierceBiotech: Benlysta review spooks investors ahead of FDA panel. Report | Follow @FierceBiotech

 @JohnCFierce: AcelRx is shooting for an $86M IPO. No product revenue, late-stage pain drug. Doesn't look all that promising. Story | Follow @JohnCFierce

> ReNeuron launches first stem cell trial for stroke. Report 

> Cracked vials force Anthera ($ANTH) to suspend PhIIb lupus study. News

> FDA advisory panel holds HGS's future in its hands. Article 

> Pfizer enrolls UCSF for $85M drug discovery pact. Story 

> Eisai gains cancer drug approval as it takes a big patent hit. Article 

 Biotech Research News

> Britain surprised at poor cancer screening. News

> Huge database helps psych drug development. Story

> Groups work to find pancreatic cancer biomarkers. Article

> Stem cells treat stroke victim. Report

> Stem cell patch heals a broken heart. News

Manufacturing News

> McKesson, IBM turn to analytics for supply chain greening. Article 

> Compliance, security and biotech to drive packaging. News 

> Filtration tech aims to ease cleanroom air handling. Report 

> Thyrogen on track after fill/finish revalidation. Story 

> Claris warned over "swirling mass" in antibiotic. Article 

> BMS suffers multimillion-dollar cargo heist. News 

And Finally... Thefts of pharmaceuticals for black market sales are on the rise, experts say. Report 

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.